BIONTECH SE SPON. ADRS 1
Commented by Nico Popp on October 17th, 2022 | 12:21 CEST
Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?
After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.
Read
Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST
Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!
Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?
Read
Commented by Fabian Lorenz on October 12th, 2022 | 11:33 CEST
TUI share soon to be a penny stock? BASF, BioNTech, Cardiol Therapeutics - buy or sell?
Buy or sell? It is not only the BASF share that is currently the subject of clearly differing opinions. While the gas price brake plans on Monday caused euphoria among investors and correspondingly rising prices for the shares of the chemical company, analysts from Goldman Sachs and Morgan Stanley continue to express pessimism. Experts are similarly cautious about the prospects for TUI. UBS even sees the share of the tourism group on the way to becoming a penny stock. Analysts are more optimistic about BioNTech, but the share is not making any headway at the moment. In contrast, experts see massive upside potential in the biotech gem Cardiol Therapeutics. Cash is now equal to market capitalization, and drug development is making progress.
Read
Commented by André Will-Laudien on October 12th, 2022 | 11:31 CEST
Biotech in the scope: BioNTech, XPhyto Therapeutics, MorphoSys, Valneva - The cards are reshuffled!
Cancer remains one of the greatest afflictions of our time, along with cardiovascular disease. Despite the tremendous progress already made in the fight against cancer, there remains an unmet medical need for many types of cancer. Cancer was responsible for nearly 10 million deaths worldwide in 2020. Other diseases, such as Alzheimer's and Parkinson's, also continue to be the focus of research. How is the biotech industry faring after the pandemic and during the stock market storm?
Read
Commented by Stefan Feulner on October 10th, 2022 | 10:43 CEST
BioNTech, Fonterelli GmbH & Co KGaA, Fonterelli SPAC 2 AG, MorphoSys - Bullish forecasts
The capital-intensive biotech and pharma sector has been stuck in a correction since the central banks changed their strategy at the beginning of the stock market year. In particular, vaccine manufacturers, which have exploded since the outbreak of COVID-19, have lost disproportionately in value since their highs in August of last year. However, the pandemic is likely to be with us for the next few years, albeit in a weakened form. The development of new drugs benefits companies that could now face a similar path as the vaccine producers.
Read
Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST
Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life
About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...
Read
Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST
Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check
The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.
Read
Commented by Juliane Zielonka on September 23rd, 2022 | 11:28 CEST
Defence Therapeutics, Amazon, BioNTech - Innovative technologies for health
While WHO Director-General Tedros Adhanom Ghebreyesus sees the end of the Corona pandemic within reach, companies like BioNTech have more products in the pipeline to bring successful drugs to market. In order to ensure that this happens thoroughly and more quickly, Canadian company Defence Therapeutics is stepping up to shorten development cycles with a unique platform technology in oncology. Cancer has still not been eradicated. An end, however, is in sight for Amazon's in-house healthcare division. Amazon Care is closing its doors at the end of the year, but the Seattle-based corporation still cannot let go of the lucrative healthcare business...
Read
Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST
BioNTech, XPhyto, Valneva - It is over!
In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.
Read
Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST
Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?
Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.
Read